Your session is about to expire
← Back to Search
APG-2575 + Palbociclib for Breast Cancer
Study Summary
This trial is testing a new cancer drug, APG-2575, by itself and in combination with another cancer drug, palbociclib. It is for patients with advanced solid tumors or metastatic breast cancer who have progressed or relapsed after first line therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 55 Patients • NCT03007979Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain cancer has spread but my symptoms are under control.My breast cancer has spread and has specific molecular features.I have previously used a Bcl-2 inhibitor.My cancer has no standard treatment options left, as confirmed by tests.I can swallow pills without any issues.I am a woman who can have children and have a recent negative pregnancy test.I haven't had any cancer treatment in the last 14 days.I am fully active and can carry on all pre-disease activities without restriction.I am in menopause naturally or through treatment.I can provide a sample of my tumor for the study, either from previous tests or by undergoing a new biopsy.I am currently experiencing symptoms from a fungal, bacterial, or viral infection.I still have side effects from previous cancer treatments that are moderate or worse.I have a heart condition affecting my heart's electrical activity.I haven't had a heart attack or heart surgery in the last 6 months.I have not had major surgery in the last 28 days or minor surgery in the last 7 days.I haven't taken any specific medications in the last 14 days.I am 18 years old or older.My organs and bone marrow are working well.
- Group 1: combination arm
- Group 2: single arm
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the upper age limit of participation in this medical trial set at 55 years old?
"According to the prerequisites of this trial, participants must be over eighteen years old and younger than 99."
What other inquiries have been conducted using APG-2575?
"APG-2575 was first researched in 2012 at Unimed Medical Institute, with 75 studies now concluded. Currently there are 133 functioning trials, many of which take place within the great city of Atlanta, Georgia."
What is the size of the sample group in this research project?
"Data found on clinicaltrials.gov affirms that this research project is actively enrolling participants; the trial was initially launched on August 13th 2021, and a recent edit occurred on August 12th 2022. Altogether, 65 volunteers need to be sourced from 4 distinct sites."
What pathologies has APG-2575 been demonstrated to alleviate?
"APG-2575 is an effective therapeutic option for individuals suffering from breast cancer, malignant neoplasms, and postmenopausal symptoms."
To whom does this clinical trial offer enrollment?
"This research study is accepting 65 individuals impacted by breast cancer, aged between 18 and 99. Eligibility criteria include having measurable or evaluable disease according to RECIST v1.1 standards; prior treatment with a CDK4/6 inhibitor for at least 8 weeks that resulted in progression or recurrence of the condition; being over 60 years old or, if younger than 60, either having undergone a bilateral oophorectomy procedure or medically confirmed ovarian failure as well as cessation of regular menses lasting 12 consecutive months without any other causes, along with serum levels of estradiol and FSH within postmenopausal female reference range"
How many health facilities are currently administering this experiment?
"This research is taking place at 4 distinct sites; Atlanta, San Antonio, Austin, and other locales. For the sake of reducing travel costs associated with participation in this trial, it is recommended that you opt for a site closest to your residence."
Are there any remaining opportunities to participate in this research endeavor?
"Affirmative. Clinicaltrials.gov verifies that this research project, originally listed on August 13th 2021, is actively searching for 65 volunteers to be enrolled across 4 distinct sites."
Share this study with friends
Copy Link
Messenger